Euroopa Liit - islandi - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Æxlishemjandi lyf - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - human fibrinogen - stungulyfs-/innrennslisstofn, lausn - 1 g

Euroopa Liit - islandi - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - svín - fyrir virkan ónæmingu svína frá 7 vikna aldri til að koma í veg fyrir dauðsföll og draga úr sýkingu og sjúkdómum af völdum svínapestarveiru (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - human albumin - innrennslislyf, lausn - 200 g/l

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - human serum albumin - innrennslislyf, lausn - 50 g/l

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - c1-hemill - stungulyfs-/innrennslisstofn og leysir, lausn - 500 a.e.

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - c1-hemill - stungulyfsstofn og leysir, lausn - 1500 a.e.

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh* - c1-hemill - stungulyfsstofn og leysir, lausn - 2000 a.e.

Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

csl behring gmbh - immunoglobulin-anti d - stungulyf, lausn - 300 míkróg

Euroopa Liit - islandi - EMA (European Medicines Agency)

intervet international bv - classical swine fever virus (csfv) -e2 undireiningu mótefnavaka - Ónæmissjúkdómar fyrir suidae - svín - virkt ónæmisaðgerðir svín frá 5 vikna aldri til að koma í veg fyrir dauðsföll og draga úr klínískum einkennum á klassískum svínakjöti, auk þess að draga úr sýkingu við og útskilnað á csf sviði veira. upphaf verndar er 2 vikur. verndartími er 6 mánuðir.